Recent Developments in Sample Management: Reflecting on the past year at Xavo and looking ahead into 2025.

Looking back at the past year, what’s been the most transformative technological milestone for Xavo, and how has it impacted your clients in the biopharma sector?

Florian Tauchert: Our initial focus was on optimizing and automating processes in small molecule compound laboratories. With the platform now refined to the point where we can seamlessly onboard even highly complex clients within weeks, we expanded its application across other laboratories in the R&D value chain. By addressing their unique operational needs, not only just providing custom properties, but through enabling their processes and way of working within our system, we’ve successfully extended the platform’s reach. This approach ensures that all users benefit from ongoing enhancements, enabling a consistent and impactful experience across diverse R&D environments.

The biopharma industry has faced significant challenges recently. How did Xavo’s platform adapt to meet evolving client needs and external pressures over the last year?

Florian Tauchert: Our platform is designed with dynamic adaptability, allowing us to modify configurations and business rules seamlessly during runtime. This flexibility enabled us to quickly enhance and refine features to address evolving client needs. We actively engage in discussions with customers and our in-house experts, ensuring we not only understand their requirements but also share best practices tailored to their operations. Additionally, we collect improvement ideas from all customers and incorporate them into regular product updates, provided free of charge. This approach has been highly valued by our users and has strengthened our role as a trusted partner in navigating industry challenges.

What new features or enhancements to Xavo’s platform were launched in the past year, and how have they shaped the user experience?

Florian Tauchert: This year, we improved our platform to better support scientists to directly order materials from laboratories. A major focus was placed on enhancing the user experience, including intuitive material selection through names or queries. Additionally, we prioritized robust handling of edge cases, such as suggesting alternatives when certain materials are unavailable and providing intuitive resolution options for these scenarios. These improvements have significantly expanded our platform's presence, integrating it more deeply into multiple stages of our customers' R&D workflows. We'll be attending the SLAS meeting in San Diego in January where we'll discuss more details about future developments of the Xavo platform, so don't miss the chance to talk with us directly!

As you look to the next year, what’s the most exciting technological advancement or feature on Xavo’s roadmap? How will it address emerging trends in biopharma R&D?

Florian Tauchert: One of the most exciting advancements on our roadmap is the introduction of global operations across multiple sites. This feature will enable users to track material availability and manage shipping and inter-site transfers. By addressing the growing need for efficient resource allocation in distributed R&D operations and outsourced CRO / CDMO activities, this capability will help our clients reduce delays, optimize costs, and accelerate their workflows. This evolution not only meets the increasing complexity of biopharma R&D but also reinforces our commitment to being a versatile and scalable solution that adapts to emerging trends in the industry.

If you were to summarize Xavo’s vision for the next year in one sentence, what would it be? What role do you see the company playing in shaping the future of biopharma labs

Florian Tauchert: The idea of a single platform managing every aspect of the R&D process is unrealistic. Instead, the R&D journey involves many distinct stages, each benefiting from specialized solutions—whether developed in-house, such as AI models for drug discovery, or provided by other vendors. Our vision is to serve as the essential backbone that integrates these diverse solutions, offering not just robust inventory management but also process knowledge and execution. By doing so, we aim to enable biopharma labs to optimize their complex ecosystems effectively. Or, as we say: We strive to Xceed the expectations of our customers. 

    Thank you Florian for the highly interesting insights!